المؤلفون: Mayuko Hori, Kaoru Yasuda, Hiroshi Takahashi, Kunio Morozumi, Shoichi Maruyama

المصدر: Scientific Reports, Vol 13, Iss 1, Pp 1-6 (2023)

مصطلحات موضوعية: Medicine, Science

الوصف: Abstract Frailty is common among hemodialysis patients and is associated with mortality and fractures. Hypomagnesemia is also known to be a risk factor for mortality and fractures and has been shown to be significantly associated with muscle performance indexes. However, little is known about the association between hypomagnesemia and frailty. We enrolled 339 outpatients who underwent hemodialysis and assessed frailty using the Clinical Frailty Scale (CFS), a 7-point subjective assessment tool based upon clinical judgment. We examined the association between serum magnesium levels and frailty evaluated using the CFS. The median CFS score was 3 points, and 49 (14.5%) patients had frailty (CFS score ≥ 5). In multiple regression analysis, serum magnesium levels were independently associated with increased CFS scores (β = − 0.126, P = 0.005) adjusted for age, body mass index, diabetes, cardiovascular diseases, prevalent fractures, serum albumin and C-reactive protein. The adjusted odds ratio for frailty was 2.85 [95% confidence interval (CI) 1.23–6.97, P = 0.014] in the lower serum magnesium group categorized based on the median value. Furthermore, with regard to model discrimination, adding serum magnesium levels to the established risk factors significantly improved net reclassification (0.520, P

وصف الملف: electronic resource

العلاقة: https://doaj.org/toc/2045-2322Test

الوصول الحر: https://doaj.org/article/85eb0eb3972a44d58660b4c936028f45Test

المؤلفون: Chika Kondo, Hiroichi Koyama, Hiroshi Takahashi, Kaoru Yasuda, Kunio Morozumi, Makoto Tsujita, Mayuko Hori, Shoichi Maruyama, Takashi Hashimoto, Tomonori Aoi, Yoshiko Mori, Yuichi Shirasawa

المصدر: Internal Medicine. 2023, 62(18):2617

المؤلفون: Hideaki Shimizu, Kaoru Yasuda, Masashi Mizuno, Reiko Muto, Shoichi Maruyama, Takuji Ishimoto, Yasuhiko Ito, Yasuhiro Suzuki

المصدر: Internal Medicine. 2023, 62(4):565

المؤلفون: Mayuko Hori, Kaoru Yasuda, Hiroshi Takahashi, Chika Kondo, Yuichi Shirasawa, Yuka Ishimaru, Yuka Sekiya, Kunio Morozumi, Shoichi Maruyama

المصدر: Scientific Reports, Vol 12, Iss 1, Pp 1-8 (2022)

مصطلحات موضوعية: Medicine, Science

الوصف: Abstract Denosumab is reported to increase bone mineral density (BMD) among haemodialysis patients; however, hypocalcaemia is a serious adverse effect among chronic kidney disease (CKD) patients. Identifying which patients will show greater improvement in BMD is important. We enrolled 84 haemodialysis patients with osteoporosis in our study. 28 patients initiated denosumab treatment between October 2019 and October 2020. We assessed BMD changes and investigated the association between baseline bone turnover marker (BTM) levels and 6-month changes in BMD after denosumab treatment. BMD was increased at 6 months in denosumab-treated patients compared with patients not treated with denosumab (lumbar spine: 5.34% vs. − 0.49%; total hip: 2.43% vs. − 0.47%). Bone-specific alkaline phosphatase (BAP) and tartrate-resistant acid phosphatase-5b (TRACP-5b) at baseline were independently associated with increased BMD in the total hip (BAP: β = 0.472, p value = 0.004; TRACP-5b: β = 0.433, p value = 0.008) and lumbar spine (BAP: β = 0.591, p value = 0.001; TRACP-5b: β = 0.613, p value = 0.0008). BAP and TRACP-5b were also independent predictors of hypocalcaemic events (OR [95% CI] 1.747 [1.084–4.604] and 1.006 [1.000–1.015], respectively). BTMs may be associated with increased BMD and hypocalcaemic events after denosumab treatment. BTM measurement may be useful for assessing the effect of denosumab on BMD; however, careful monitoring of serum calcium levels is needed.

وصف الملف: electronic resource

العلاقة: https://doaj.org/toc/2045-2322Test

الوصول الحر: https://doaj.org/article/795183f02b114c23992bcfbb4fe39255Test

المؤلفون: Munekazu Ryuzaki, Yasuhiko Ito, Hidetomo Nakamoto, Yuichi Ishikawa, Noritomo Itami, Minoru Ito, Atsushi Ueda, Yoshie Kanazawa, Hideki Kawanishi, Yoshihiko Kanno, Hitoshi Sugiyama, Kazuhiko Tsuruya, Hiroyuki Terawaki, Tadashi Tomo, Mizuya Fukasawa, Akihiro C. Yamashita, Hideki Yokoi, Masaaki Nakayama, Hidemichi Yuasa, Yasushi Tsujimoto, Hiraku Tsujimoto, Yosuke Saka, Yusuke Kuroki, Kaoru Yasuda, Takayuki Fujii, Atsuhiro Kanno, Emi Fujikura, Kimio Watanabe, Yoko Obata, Miho Murashima, Naohiro Toda, Shuto Yamamoto, Yoshihiro Tsujimoto, Tsutomu Sakurada, Daisuke Komukai, Kiyotaka Uchiyama, Naoki Washida, Kohkichi Morimoto, Takahiro Kasai, Yukio Maruyama, Chieko Higuchi, Hiroaki Io, Keiichi Wakabayashi, on behalf of the Working Group on Revision of Peritoneal Dialysis Guidelines of the Japanese Society for Dialysis Therapy

المصدر: Renal Replacement Therapy, Vol 7, Iss 1, Pp 1-20 (2021)

مصطلحات موضوعية: Diseases of the genitourinary system. Urology, RC870-923

الوصف: Abstract Background This article is a duplicated publication from the Japanese version of “2019 JSDT Guidelines for Peritoneal Dialysis” with permission from the Japanese Society for Dialysis Therapy (JSDT). This clinical practice guideline (CPG) was developed primarily by the Working Group on Revision of Peritoneal Dialysis (PD) Guidelines of the Japanese Society for Dialysis Therapy. Recently, the definition and creation process for CPGs have become far more rigorous; traditional methods and formats no longer adhere to current standards. To improve the reliability of international transmission of our findings, CPGs are created in compliance with the methodologies developed by the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) working group. Part 2 of this PD guideline is the first CPG developed by our society that conforms to the GRADE approach. Methods Detailed processes were created in accordance with the Cochrane handbook and the GRADE approach developed by the GRADE working group. Results Clinical question (CQ)1: Is the use of renin-angiotensin system inhibitors (RAS inhibitors), such as angiotensin-converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARB), effective in PD patients? Recommendation: We suggest the usage of RAS inhibitors (ACEI and ARB) in PD patients (GRADE 2C). CQ2: Icodextrin or glucose solution: which is more useful as a dialysate among patients with PD? Recommendation: We suggest using icodextrin when managing body fluids in PD patients (GRADE 2C). CQ3: Is it better to apply or not apply mupirocin/gentamicin ointment to the exit site? Recommendation: We suggest not applying mupirocin/gentamicin ointment to the exit sites of PD patients (GRADE 2C). CQ4: Which surgical approach is more desirable when a PD catheter is placed, open surgery or laparoscopic surgery? No recommendation. CQ5: Which administration route of antibiotics is better in PD patients with peritonitis, intravenous or intraperitoneal? Recommendation: We suggest intraperitoneal administration of antibiotics in PD patients with peritonitis (GRADE 2C). Note: The National Insurance does not currently cover intraperitoneal administration. CQ6: Is peritoneal dialysis or hemodialysis better as the first renal replacement therapy in diabetic patients? No recommendation. Conclusions In the future, we suggest that society members construct their own evidence to answer CQs not brought up in this guideline, and thereby show the achievements of Japan worldwide.

وصف الملف: electronic resource

العلاقة: https://doaj.org/toc/2059-1381Test

الوصول الحر: https://doaj.org/article/b2bc12191c924667b9fa46d1f0918730Test

المؤلفون: Takafumi Nakayama, Junki Yamamoto, Toshikazu Ozeki, Yoshiro Tsuruta, Masashi Yokoi, Tomonori Aoi, Yoshiko Mori, Mayuko Hori, Makoto Tsujita, Yuichi Shirasawa, Chika Kondo, Kaoru Yasuda, Minako Murata, Yuko Kinoshita, Shigeru Suzuki, Michio Fukuda, Chikao Yamazaki, Noriyuki Ikehara, Makoto Sugiura, Toshihiko Goto, Hiroya Hashimoto, Kazuhiro Yajima, Shoichi Maruyama, Kunio Morozumi, Yoshihiro Seo

المصدر: Biomedicines, Vol 11, Iss 2, p 592 (2023)

مصطلحات موضوعية: ABO blood type, hemodialysis, cardiovascular event, cerebrovascular event, Biology (General), QH301-705.5

الوصف: The clinical impact of ABO blood type on cardio-cerebrovascular outcomes in patients undergoing dialysis has not been clarified. A total of 365 hemodialysis patients participated in the current study. The primary endpoint was defined as a composite including cardio-cerebrovascular events and cardio-cerebrovascular death. The primary endpoint was observed in 73 patients during a median follow-up period of 1182 days, including 16/149 (11%) with blood type A, 22/81 (27%) with blood type B, 26/99 (26%) with blood type O, and 9/36 (25%) with blood type AB. At baseline, no difference was found in the echocardiographic parameters. Multivariable Cox regression analyses revealed that blood type (type A vs. non-A type; hazard ratio (HR): 0.46, 95% confidence interval (95% CI): 0.26–0.81, p = 0.007), age (per 10-year increase; HR: 1.47, 95% CI: 1.18–1.84), antiplatelet or anticoagulation therapy (HR: 1.91, 95% CI: 1.07–3.41), LVEF (per 10% increase; HR: 0.78, 95% CI: 0.63–0.96), and LV mass index (per 10 g/m2 increase; HR: 1.07, 95% CI: 1.01–1.13) were the independent determinants of the primary endpoint. Kaplan–Meier curves also showed a higher incidence of the primary endpoint in the non-A type than type A (Log-rank p = 0.001). Dialysis patients with blood type A developed cardio-cerebrovascular events more frequently than non-A type patients.

وصف الملف: electronic resource

العلاقة: https://www.mdpi.com/2227-9059/11/2/592Test; https://doaj.org/toc/2227-9059Test

الوصول الحر: https://doaj.org/article/e2b3188bc39c44f8ada27b55741ac17dTest

المؤلفون: Hiromi OGAWA, Hiromitsu KAWAJIRI, Kae WANIKAWA, Kaoru YASUDA, Makiko KODAMA, Satoshi IKEDA, Takashi KAWAGUCHI, Takeshi CHIKURINJI, 保田 香織, 児玉 真樹子, 小川 ひろみ, 川口 隆司, 川尻 博満, 池田 吏志, 竹林地 毅, 鰐川 華衣

المصدر: 美術教育学：美術科教育学会誌 / The Journal for the Association of Art Education. 2022, 43:35

المؤلفون: Minoru Ito, Yosuke Saka, Yusuke Kuroki, Kaoru Yasuda, Hiraku Tsujimoto, Yasushi Tsujimoto, Hidemichi Yuasa, Munekazu Ryuzaki, Yasuhiko Ito, Hidetomo Nakamoto

المصدر: Renal Replacement Therapy, Vol 5, Iss 1, Pp 1-14 (2019)

مصطلحات موضوعية: Peritoneal dialysis, Renin-angiotensin system inhibitors, Residual renal function, Systematic review, Diseases of the genitourinary system. Urology, RC870-923

الوصف: Abstract Background Renin-angiotensin system inhibitors (RASIs), either angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, are widely used in patients with non-dialysis chronic kidney disease, as a renin-angiotensin system (RAS) blockade has renoprotective effects. Several studies show that preserving residual renal function is important for a better prognosis in peritoneal dialysis (PD) patients. Here, we systematically reviewed the beneficial or harmful effects of RAS blockade in PD patients. Methods PubMed, the Cochrane Library, Embase, the Ichushi web databases, and other resources were selected to search clinical guidelines, systematic reviews, and randomized controlled trials (RCT) published before April 14, 2017, using “peritoneal dialysis,” “angiotensin-converting enzyme inhibitors,” “angiotensin II type 1 receptor blockers,” and “randomized controlled trial” as keywords. Desired results were total mortality, technical survival, urine volume, residual renal function calculated by glomerular filtration rate (GFR), cardiovascular events, and anuria progression rate. The study protocol is registered in PROSPERO (International Prospective Register of Systematic Reviews) under the registration number CRD42018104106. Results Of a total of 339 studies, eight were identified as suitable for the analysis. Only one study was blinded, whereas the other seven studies were open-label. RASI appeared to preserve residual renal function, GFR (4 studies, 163 participants, mean difference [MD] 0.97 mL/min/1.73 m2, 95% confidence interval [CI] 0.49–1.44), and urine volume (6 studies, 194 participants, MD 142.56 mL 95% CI 25.42–259.69), although there were no beneficial effects of RASI on total mortality, technical survival, cardiovascular events, and anuria rate. Conclusions Our analysis found that RASIs contribute to preserving GFR and urine volume in PD patients. As the number of study participants is small, further studies with a larger sample size are required.

وصف الملف: electronic resource

العلاقة: http://link.springer.com/article/10.1186/s41100-019-0238-3Test; https://doaj.org/toc/2059-1381Test

الوصول الحر: https://doaj.org/article/784c23d8ab0b4ec791aefb4173797492Test

المؤلفون: Mayuko Hori, Kaoru Yasuda, Hiroshi Takahashi, Chikao Yamazaki, Kunio Morozumi, Shoichi Maruyama

المصدر: PLoS ONE, Vol 16, Iss 5, p e0251912 (2021)

مصطلحات موضوعية: Medicine, Science

الوصف: IntroductionBone mineral density (BMD) measured with dual-energy X-ray absorptiometry (DXA) can be used to predict fractures, but its clinical utility has not been fully established in chronic kidney disease (CKD) patients. Magnesium is an essential trace element. Although magnesium is associated with the risk of fractures in non-CKD populations, the relationship is unknown in CKD patients.MethodsBMD and serum magnesium levels were measured in 358 stable outpatients undergoing maintenance hemodialysis therapy. The primary outcome was fragility fracture. Patients were divided into groups according to the median level of magnesium and the normal threshold value of lumbar spine BMD.ResultsDuring the median follow-up period of 36 months, 36 (10.0%) fractures occurred. The cumulative incidence rates of fractures were 17.6% and 5.2% [adjusted hazard ratio (aHR) 2.31, 95% confidence interval (CI) 1.03-5.17, P = 0.030] in the lower (Discussion/conclusionsThe combination of serum magnesium and lumbar spine BMD can be used for fracture risk stratification and synergistically improves the prediction of fractures in CKD patients.

وصف الملف: electronic resource

العلاقة: https://doaj.org/toc/1932-6203Test

الوصول الحر: https://doaj.org/article/a42cb69e8262498aadc9c90bf348feceTest

المؤلفون: Fumihiko Matsui, Hiroshi Daimon, Hirosuke Matsui, Kaoru Yasuda, Masayoshi Fujita, Naoyuki Maejima, Rie Horie, Ryo Ishii, Satoshi Kitagawa, Tomohiro Matsushita, 前島 尚行, 北川 哲, 堀江 理恵, 大門 寛, 安田 馨, 松下 智裕, 松井 公佑, 松井 文彦, 石井 良, 藤田 將義

المصدر: SPring-8/SACLA利用研究成果集 / SPring-8/SACLA Research Report. 2017, 5(2):161